Know Labs, Inc. announced the appointment of three new members to the company?s Board of Directors. These appointments increase the number of Directors to seven. Each new Director brings to the board extensive sector-relevant experience with deep knowledge of the science and the marketplace that is the focus of Know Labs.

The new appointees are John Cronin, Larry Ellingson and Tim Londergan. John Cronin is the founder and CEO of ipCapital Group, Inc., a leading global advisory company on intellectual property strategy and monetization. Cronin began his career at IBM where he was the sole inventor of breakthrough chip design technology that became the company?s most valuable patent, generating $500 million in revenue.

He went on to create the IBM Patent Factory and grew IBM?s patent portfolio from ninth to number one in the world. He played a pivotal role in increasing IBM?s patent licensing revenue from $30 million to over $2 billion a year. Cronin has been a strategic advisor and consultant to Know Labs, supporting the company?s expanding patent portfolio from 86 to 246 patents issued, pending and in process over the last twelve months, increasing its global leadership in the non-invasive blood glucose monitoring category.

Larry Ellingson has been a member of Know Labs? Medical Advisory Board for the past four years. Ellingson?s insight and global relationships have been instrumental in shaping Know Labs?

strategy and opening important doors in the diabetes industry. Ellingson?s background includes 30 years with Eli Lilly where he headed the multibillion-dollar annual revenue Diabetes Care business unit. Ellingson has been an advocate for accessible and affordable diagnosis and treatment through his activities with diabetes focused non-profit organizations.

Among his many activities he has served as Chairman of the Board of the American Diabetes Association and has been the Vice-Chairman of the Board of the Diabetes Leadership Council for the last several years. Tim Londerganis the founder and CEO of Tangibly, Inc., developer of the globe?s pre-eminent trade secret management platform. Trade secrets are a key component of an IP asset base and include the company?s proprietary algorithms. Londergan has a Ph.D. in Chemistry and experience as a CEO and COO of technology companies, including Lumera, Wavefront Venture Labs and Operem.

He spent several years as Head of Commercial Development at Intellectual Ventures--a six-billion-dollar global intellectual property fund. In that role he managed a project between Intellectual Ventures and Know Labs to enhance Know Labs? IP portfolio.

Recently, Londergan was named IAM 300 World?s Leading IP Strategist 2023.